Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers
- RESPIRATORY DISORDERS THERAPEUTICS MARKET, GLOBAL, MERCK & CO. ANNUAL REVENUE
S BESTSELLING RESPIRATORY TREATMENT THROUGHOUT THE FORECAST PERIOD.
PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025
- CHIESI'S COPD PORTFOLIO ASSESSMENT, 2017
- 10.3.3 CHIESI
IN 2007, ASTRAZENECA ACQUIRED MEDIMMUNE AND ITS MANY RESPIRATORY DRUGS THAT WERE IN DEVELOPMENT AT THAT TIME.
Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market
Beyond these two drugs, the company' s other respiratory complications therapies will contribute very little revenue.
Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way
There are five main molecular targets within the respiratory therapy.
- GLOBAL RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET
SEGMENTATION OF GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET BY TYPE OF DRUG 2015 Off-label drugs ##% THIS SEGMENT CONSISTS OF A SINGLE APPROVED DRUG, SYNAGIS, WHICH IS A LARGE MOLECULE DRUG.
Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns
Respiratory Merck (2013).
- TEVA'S AR PORTFOLIO ASSESSMENT, 2014
GSK CURRENTLY HAS THE WORLD' S MOST SUCCESSFUL RESPIRATORY DRUG FRANCHISE.